|
| Study (year) | Region | Study design | Date source | Sample size | Stage | Reference group | Time period | HR (95% CI) | Adjustment variables |
|
| Ko et al. 2014 [20] | USA | Retrospective cohort study | NCI and NCCN designated academic institutions | 363 | All | Nonmetformin | 2005–2010 | 0.43 (0.24, 0.77) | Age, stage, grade, histology, and adjuvant treatment |
| Nevadunsky et al. 2014 [25] | USA | Retrospective cohort study | Montefiore Medical Center (MMC)/Albert Einstein College of Medicine | 985 | All | Nonmetformin | 1999–2009 | 0.54 (0.30, 0.97) | Age, clinical stage, grade, chemotherapy treatment, radiation treatment, and
presence of hyperlipidemia |
| Lemańska et al. 2015 [26] | Poland | Retrospective cohort study | Department of Gynecologic Oncology of Poznan University of Medical Sciences | 107 | All | Nonmetformin | 2002–2010 | 1.08 (0.46, 2.56) | NR |
| Ezewuiro et al. 2016 [27] | USA | Retrospective cohort study | The University of Chicago Medical Center (UCMC) | 58 | III, IV, and recurrence | Nonmetformin | 1992–2011 | 0.42 (0.23, 0.78) | Study site, stage (III versus IV/recurrent), and age at chemotherapy |
| Seebacher et al. 2016 [28] | Austria | Retrospective cohort study | Department of Gynaecology and Gynaecological Oncology of
the Medical University of Vienna | 465 | All | Nonmetformin | 1995–2001 | 0.90 (0.69, 1.20) | NR |
| Al Hilli et al. 2016 [21] | USA | Retrospective cohort study | Patient database of Mayo Clinic, Rochester, Minnesota | 138 | All | Nonmetformin | 1999–2008 | 0.61 (0.30, 1.23) | Propensity score |
|
